1. Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain;Craig;PT,2010
2. Endo Pharmaceuticals announces reformulated version of Opana ER with INTAC technology designed to be crush-resistant accounts for more than 90 percent of Opana ER total prescription volume. PR Newswire. September 6, 2012. http://www.prnewswire.com/news-releases/endo-pharmaceuticals-announces-reformulated-version-of-opana-er-with-intac-technology-designed-to-be-crush-resistant-accounts-for-more-than-90-percent-of-opana-er-total-prescription-volume-168750546.html. Accessed July 31, 2013.
3. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse—Tennessee, 2012;MMWR Morb Mortal Wkly Rep,2013
4. US Food and Drug Administration (FDA). FDA warns about serious blood disorder resulting from misuse of Opana ER. October 11, 2012, and November 1, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm322432.htm. Accessed August 8, 2013.
5. Centers for Disease Control and Prevention (CDC). Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER. Health Alert Network (HAN). October 26, 2012. http://www.bt.cdc.gov/han/han00331.asp. Accessed August 8, 2013.